Physician profile
Jeffrey William Groves
NPI 1629196399
$627,523.52
in general payments reported to CMS, 2019-2025
53 companies · $90K in 2025
The $90K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $73K · 2021: $144K · 2022: $113K · 2023: $69K · 2024: $73K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $160K · Honoraria: $30K · Consulting Fee: $27K · Food and Beverage: $11K · Travel and Lodging: $3,173 · Education: $39.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $160,155.00 |
| Honoraria | $30,412.50 |
| Consulting Fee | $27,402.66 |
| Food and Beverage | $10,502.32 |
| Travel and Lodging | $3,173.24 |
| Education | $39.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175,244.15 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $94,756.70 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Biohaven Pharmaceuticals, INC. | $77,891.33 | 2020-2021 | |
| Lundbeck LLC | $60,601.85 | 2019-2025 | Vyepti |
| Impel Pharmaceuticals INC. | $35,370.80 | 2022-2023 | Trudhesa |
| Allergan, INC. | $30,417.49 | 2019-2021 | |
| Pfizer INC. | $29,512.78 | 2023-2025 | |
| Amgen INC. | $26,912.36 | 2019-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $25,481.57 | 2019-2025 | Kisunla, Amyvid |
| Argenx US, INC. | $16,171.88 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceutical Holding Company Ltd. | $13,042.09 | 2022 | |
| Ucb, INC. | $10,849.22 | 2023-2025 | Rystiggo, Zilbrysq |
| E.R. Squibb & Sons, L.L.C. | $9,445.43 | 2020-2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $6,916.52 | 2021-2022 | |
| Celgene Corporation | $4,577.96 | 2021-2025 | Zeposia |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $3,469.84 | 2025 | Symbravo |
| Sk Life Science, INC. | $1,409.24 | 2020-2025 | |
| Medtronic, INC. | $1,087.86 | 2021-2025 | Percept Pc Brainsense, Sensight |
| Livanova USA, INC. | $919.96 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $730.99 | 2019-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $368.26 | 2019-2020 | |
| Biogen, INC. | $362.53 | 2019-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $295.36 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $196.74 | 2022-2025 | Ingrezza, Ongentys |
| Medtronic USA, INC. | $194.40 | 2019 | |
| Adamas Pharmaceuticals, INC. | $157.00 | 2019 | |
| Ani Pharmaceuticals, INC. | $135.61 | 2023 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $126.69 | 2020-2025 | Acthar |
| Mdd US Operations, LLC | $123.90 | 2021-2024 | Gocovri, Gocovri |
| Boston Scientific Corporation | $87.18 | 2019-2022 | |
| Emd Serono, INC. | $86.56 | 2019-2022 | |
| Abbott Laboratories | $84.07 | 2019-2023 | Infinity |
| Catalyst Pharmaceuticals, INC. | $60.20 | 2024 | |
| Eisai INC. | $53.41 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $34.46 | 2019-2022 | |
| Grifols USA, LLC | $30.95 | 2023-2025 | Gamunex-C |
| Tg Therapeutics, INC. | $30.82 | 2023-2024 | |
| Genentech USA, INC. | $28.77 | 2019-2020 | |
| Neurelis, INC. | $28.68 | 2020-2025 | Valtoco |
| Greenwich Biosciences, INC. | $24.80 | 2019 | |
| Zyla Life Sciences, INC. | $24.13 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.37 | 2019 | |
| Neuropace, INC. | $20.25 | 2024 | |
| Csl Behring | $19.46 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.53 | 2023 | Keveyis |
| Averitas Pharma INC. | $16.52 | 2023 | Qutenza |
| Promius Pharma LLC | $16.46 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.97 | 2024 | |
| Acorda Therapeutics, INC | $13.51 | 2019 | |
| Genzyme Corporation | $13.17 | 2022 | |
| Sumitomo Pharma America, INC. | $13.06 | 2023 | Aptiom |
| Life Molecular Imaging Ltd | $10.68 | 2025 | Neuraceq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Groves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.